Why Revance Therapeutics Stock Is Bolting Higher Today
Shares of Revance Therapeutics (NASDAQ: RVNC) are up by a respectable 15.8% as of 11:08 a.m. EDT Wednesday morning. The biopharma's stock is regaining some of its lost ground after yesterday's unfortunate 22% dip.
Shares of Revance hit the skids yesterday following the public disclosure of a Form 483 stemming from a Freedom of Information Act request directed at the U.S. Food and Drug Administration (FDA). This regulatory form noted issues with the company's manufacturing process for DaxibotulinumtoxinA injection, an experimental treatment for glabellar lines. Glabellar lines are the lines on your forehead that can deepen with age.
Image source: Getty Images.
Source Fool.com
